Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ultrapure Biotech Sodium Chondroitin is a patented, non-sulphated biotechnological glycosaminoglycan developed by Altergon Italia for injectable pharmaceutical applications. Produced through a proprietary fermentation and purification process at a dedicated biotechnology facility in Italy, this molecule is designed as a high-purity raw material for use in orthopedics, ophthalmology, and urology. In the treatment of osteoarthritis, it is notably utilized in combination with hyaluronic acid for intra-articular injections, where it serves as a technological excipient that regulates viscosity and enhances the therapeutic properties of the formulation. Its biotechnological origin ensures a high degree of purity and consistency compared to traditional animal-derived chondroitin sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ultrapure Biotech Sodium Chondroitin.